Lumos Pharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Austin, texas, april 18, 2024 (globe newswire) -- lumos pharma, inc. (nasdaq:lumo), a biopharmaceutical company advancing an oral therapeutic candidate for pediatric growth hormone deficiency (pghd) through phase 2 clinical trials, announced today that abstracts reviewing data from its phase 2 oragrowth210 and oragrowth212 trials will be presented at several upcoming medical meetings in the us and europe.

Austin, texas, march 20, 2024 (globe newswire) -- lumos pharma, inc. (nasdaq:lumo), a biopharmaceutical company advancing an oral therapeutic candidate for pediatric growth hormone deficiency (pghd) through phase 2 clinical trials, announced that on thursday, march 14, 2024, the company received a notice of allowance from the us patent and trade office (uspto) for claims in its patent application number pct/us22/050700 titled “compactable oral formulations of ibutamoren.” this patent contains claims directed to certain improved formulations of lum-201 the company intends to utilize in its phase 3 trial and ultimately commercialize. this grant of this novel formulation patent extends intellectual property protection through november 2042 for these improved versions of lum-201 drug product.

End of phase 2 meeting to occur in q2 2024, initiation of lum-201 phase 3 trial expected in q4 2024 previously announced topline data from phase 2 oragrowth210 and oragrowth212 trials of lum-201 in moderate pghd met all primary and secondary endpoints pisit “duke” pitukcheewanont, md, appointed chief medical officer conference call today at 4:30 pm est austin, texas, march 07, 2024 (globe newswire) -- lumos pharma, inc. (nasdaq:lumo), a late-stage biopharmaceutical company advancing an oral therapeutic candidate for moderate pediatric growth hormone deficiency (pghd), today announced financial results for the year ended december 31, 2023 and provided an update on clinical and regulatory activity...

Austin, texas, feb. 26, 2024 (globe newswire) -- lumos pharma, inc. (nasdaq:lumo), a biopharmaceutical company advancing an oral therapeutic candidate for pediatric growth hormone deficiency (pghd) through phase 2 clinical trials, announced it will report its full year 2023 financial results after market close on thursday, march 7, 2024. the company will host a conference call and webcast at 4:30 pm et that day to discuss these financial results and provide an update on clinical and corporate activities. a question-and-answer session will follow the prepared remarks.

Austin, texas, feb. 05, 2024 (globe newswire) -- lumos pharma, inc. (nasdaq:lumo), a biopharmaceutical company advancing an oral therapeutic candidate for moderate pediatric growth hormone deficiency (pghd), announced today that the company will participate in the oppenheimer 34th annual healthcare life sciences conference, to be held virtually february 13-14, 2024. lumos pharma's management will present and host virtual one-on-one meetings with the investment community on wednesday, february 14 during the event.

AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results after market close on Thursday, March 7, 2024. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.

Lumos Pharma (LUMO) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to loss of $0.86 per share a year ago.

AUSTIN, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11th – 13th and the Cantor Global Healthcare Conference 2023 being held September 26th – 28th in New York City. Lumos Pharma management will present and host one-on-one meetings at both conferences.

Lumos Pharma, Inc. (NASDAQ:LUMO ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Lisa Miller – Senior Director of Investor Relations Rick Hawkins – Chief Executive Officer and Chairman Lori Lawley – Chief Financial Officer John McKew – President and Chief Scientific Officer Duke Pitukcheewanont – Senior Vice President of Global Clinical Development and Medical Affairs Conference Call Participants Yasmeen Rahimi – Piper Sandler Leland Gershell – Oppenheimer Ed White – H.C. Wainwright Catherine Novack – Jones Trading Pete Stavropoulos – Cantor Fitzgerald Operator Good afternoon, and welcome to Lumos Pharma's Q2 2023 Financial Results Conference Call.

AUSTIN, Texas, July 26, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its second quarter 2023 financial results after market close on Wednesday, August 9, 2023. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.

Lumos Pharma (LUMO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $0.92 per share a year ago.

AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its first quarter 2023 financial results after market close on Wednesday, May 3, 2023. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.

Lumos (LUMO) delivered earnings and revenue surprises of -3.16% and 48.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AUSTIN, Texas, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2022 financial results after market close on Wednesday, March 1, 2023. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.

Lumos (LUMO) delivered earnings and revenue surprises of 14.85% and 24.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?